Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Moodys
Queensland Health
Accenture
Dow
Colorcon
Teva
Baxter
Daiichi Sankyo

Generated: August 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022055

« Back to Dashboard

NDA 022055 describes ALTABAX, which is a drug marketed by Aqua Pharms Llc and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ALTABAX profile page.

The generic ingredient in ALTABAX is retapamulin. Two suppliers are listed for this compound. Additional details are available on the retapamulin profile page.
Summary for 022055
Tradename:ALTABAX
Applicant:Aqua Pharms Llc
Ingredient:retapamulin
Patents:3
Generic Entry Opportunity Date for 022055
Generic Entry Date for 022055*:
Constraining patent/regulatory exclusivity:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022055
Ingredient-typepleuromutilin
Suppliers and Packaging for NDA: 022055
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALTABAX retapamulin OINTMENT;TOPICAL 022055 NDA Aqua Pharmaceuticals, LLC 16110-518 N 16110-518-15
ALTABAX retapamulin OINTMENT;TOPICAL 022055 NDA Aqua Pharmaceuticals, LLC 16110-518 N 16110-518-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;TOPICALStrength1%
Approval Date:Apr 12, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 14, 2027Product Flag?Substance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Aug 30, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
Patent:➤ Try a Free TrialPatent Expiration:Apr 12, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
US Army
Julphar
Moodys
QuintilesIMS
Express Scripts
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.